Sanofi's multiple sclerosis pipeline, which has shown promise of late, has suffered a setback with the news that oditrasertib, partnered with Denali Therapeutics Inc., has failed in a mid-stage study.
The demise of oditrasertib, formerly known as SAR443820/DNL788, was revealed by Denali in a brief US Securities and Exchange Commission...